Colin Goding
Scientist
Ludwig Institute for Cancer Research, Nuffield Clinical Medi
University of Oxford
United Kingdom
Biography
I completed a PhD in virology at the National Institute for Medical Research, London, UK. I then did postdoctoral work in Pierre Chambon’s lab in Strasbourg, France, where I developed an interest in transcription regulation before taking up a position at the Marie Curie Research Institute, Oxted, UK, to continue working on gene regulation, both in S. cerevisiae, as well as in melanocytes and melanoma. In 2008 I moved to the Ludwig Institute, where I continue to examine the role of signaling and transcription in melanoma biology, with the aim of developing novel and anti-cancer therapies that take tumor heterogeneity into account.
Research Interest
Transcription regulation, gene regulation, melanoma biology, and anti-cancer therapies
Publications
-
Goodall J, Carreira S, Denat L, Kobi D, Davidson I, Nuciforo P, Sturm RA, Larue L, and Goding CR. Brn-2 represses Microphthalmia-associated transcription factor expression and marks a distinct population of microphthalmia-associated transcription factor negative-melanoma cells. Cancer Res. 2008 Oct 1;68(19):7788-94.
-
Lu M, Breyssens H, Salter V, Zhong S, Hu Y, Baer C, Ratnayaka I, Sullivan A, Brown N, Endicote J, Knapp S, Kessler BM, Middleton MR, Siebold C, Jones EY, Sviderskaya EV, Cebon J, John T, Caballero OL, Goding CR and Lu X. (2013) Restoring p53 function in human melanoma cells by inhibiting mdm2 and cyclinB1/cdk1-phosphorylated nuclear iASPP. Cancer Cell. 2013 May 13;23(5):618-33.
-
Saez-Ayala M, Montenegro MF, Sanchez-del-Campo L., Fernandez-Perez MP, Chazarra S, Freter R, Middleton M, Pinero-Madrona A, Cabezas-Herrera J, Goding CR and Rodriguez-Lopez JN. Directed phenotype-switching as an effective anti-melanoma strategy. Cancer Cell. 2013 Jul 8;24(1):105-19.
-
Goding CR, Pei D, Lu X. Cancer: pathological nuclear reprogramming? Nat Rev Cancer. 2014 Aug;14(8):568-73. Epub 2014 Jul 17.
